Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

March 30, 2020

Study Completion Date

March 30, 2020

Conditions
Parkinson's Disease Aggravated
Interventions
DRUG

sodium phosphate enema, oral rifaximin and polyethylene glycol

Patients were hospitalized for 4-5 hours to receive two saline colon enemas with sodium phosphate Fleet®, 2 to 3 hours apart, appropriate hydration was provided during the procedure. If signs of fecal impaction were observed, the stools were removed manually prior to the first enema. Patients were discharged with oral treatment consistent with rifaximin 200 mg three times a day for 7 days and polyethylene glycol-3350, 17 gr per day in water for 10 days, but it was continued if necessary. Importantly, no modifications in time and dose of dopaminergic therapy or anti-dyskinetic medication (i.e. amantadine) were done at baseline or during the study

Trial Locations (1)

37160

Torre Medica Sante, León

All Listed Sponsors
lead

Torre Médica Santé

NETWORK

NCT04730245 - Microbiota Modification for the Treatment of Motor Complication of Parkinson´s Disease | Biotech Hunter | Biotech Hunter